Ronan O’Hagan, PhD

< back

Ronan O’Hagan, PhD is Senior Vice President of Research and Translational Sciences at Xilio Therapeutics. Prior to Xilio, Ronan served as Executive Director, Oncology Discovery at Merck Research Laboratories. In this role he led the oncology discovery program at Merck with a particular emphasis on approaches to enable and enhance immune-modulatory therapies in cancer. Earlier at Merck, he led target identification and validation for oncology and generated an early-discovery pipeline including both biologics and small-molecule programs. He has helped to bring multiple small-molecule and biologics programs into clinical development during his time in industry. His academic career included undergraduate and graduate work in Canada followed by post-doctoral work at the Dana Farber Cancer Institute (DFCI). In Dr. Ron DePinho’s laboratory at DFCI, he focused on genetically engineered mouse models of cancer and novel approaches to target discovery.